DOI: https://doi.org/10.54393/pbmj.v9i1.1325

PAKISTAN BIOMEDICAL JOURNAL
https://www.pakistanbmj.com/journal/index.php/pbmj/index
ISSN (E): 2709-2798, (P): 2709-278X
Volume 9, Issue 01 (January 2026)

Review Article

OPEN ACCESS

Innovative Therapeutic Paradigms in Diabetes Mellitus: Current Progress and Future Directions

Amna Sattar[1*]

[1]Department of Medicine, Jining Medical University, China

ARTICLE INFO

Keywords:
Diabetes Mellitus, Nanotechnology, Intestinal Microbiota, Insulin

How to Cite:
Sattar, A. (2026). Innovative Therapeutic Paradigms in Diabetes Mellitus: Current Progress and Future Directions: Novel Therapeutic Paradigms in Diabetes Management. Pakistan BioMedical Journal, 9(1), 03-10. https://doi.org/10.54393/pbmj.v9i1.1325

Corresponding Author:
Amna Sattar
Department of Medicine, Jining Medical University, China
amnasattar2006@gmail.com

Received Date: 10th November, 2025
Revised Date: 27th December, 2025
Acceptance Date: 23rd January, 2026
Published Date: 31st January, 2026

ABSTRACT

Diabetes mellitus is a chronic metabolic disease that is marked by inadequate glucose control that leads to eventual complications in the cardiovascular, renal, neurological, and ocular systems. The conventional approaches to treatment, such as insulin injections, oral hypoglycemic drugs, and structured lifestyle changes, continue to be the predominant approaches to treatment. However, the techniques are commonly limited so as to contain the symptoms and not achieve a long-lasting remission or to cure the causes of the disease. This has altered the field of science in the recent past, where creative approaches towards treatment have been given focus to change or even reverse the stages of disease. Stem cell interventions have the potential to cure pancreatic β-cells, and genetic therapy is meant to fix the genetic defects that lead to the disease. Immunotherapy transplantation is being undertaken to protect the β-cells in diabetes type 1 diabetes, and nanotechnology and smart insulin delivery systems can provide more precise glycemic control. In addition, the intestinal microbiota modulation has also become one of the promising adjunctive mechanisms. This review gives these new methodologies, the current status of these methodologies, and the possibilities of these methodologies in the management of diabetes.

INTRODUCTION

The term diabetes mellitus (DM) describes a set of chronic metabolic disorders, which are characterized by the constant high levels of blood glucose caused by impairments in the process of insulin secretion, its action, or both [1]. The disease is significant in terms of morbidity and mortality because it leads to damages of various organs, including the heart, kidneys, nerves, and eyes [2]. The world has been facing a social health crisis due to diabetes. According to the reference sources, over 540 million adults are already living with diabetes, and it is projected to reach 783 million people by the year 2045 (IDF, 2021). It is estimated that in 2021, 6.7 million deaths were related to diabetes in the global context, and it consumed an enormous sum of healthcare expenditure annually, estimated at USD 1 trillion (IDF, 2021).

Despite significant advances in innovative diabetes therapies, substantial research gaps remain in establishing their long-term safety, efficacy, and cost-effectiveness across diverse populations. Most emerging interventions, including stem cell therapy, gene editing, and nanotechnology-based systems, are supported primarily by early-phase trials with limited large-scale randomized evidence. Additionally, variability in treatment protocols and patient selection restricts generalizability and clinical translation. Future research should prioritize standardized methodologies, longitudinal studies, and equitable accessibility to ensure these therapies can be effectively integrated into routine diabetes care.

The rising prevalence rate and economic burden of this problem are signs of the urgent need to find effective

DOI: https://doi.org/10.54393/pbmj.v9i1.1325

treatments [3]. Diabetes mellitus is of two major types and of various other types [4] (Figure 1).

Figure 1: Types of Diabetes

Therefore, this review aims to synthesize recent advances in novel diabetes therapies and highlight key challenges and future directions for clinical translation.

Type 1 Diabetes Mellitus (T1DM)

T1DM is an autoimmune disorder in which the body's immune system assaults the β-cells of the pancreas, leading to a complete lack of insulin. It usually happens during childhood or adolescence, but more cases that happen in adults are increasingly becoming familiar. The long-term aspect of insulin therapy allows T1DM patients to live, and even with insulin treatment, these patients remain susceptible to such complications as diabetic ketoacidosis and long-term vascular damage [5].

Type 2 Diabetes Mellitus (T2DM)

T2DM is the most prevalent type, and more than 90% of all cases of diabetes are covered. It takes place due to muscle, fat, and liver insulin resistance along with progressive β-cell dysfunction [6]. Obesity, sedentary lifestyle, poor dietary decisions, and hereditary predisposition are the risk factors. T2DM is a disease that is normally not diagnosed for many years, and therefore, people are diagnosed when it is too late and when they have already developed complications [7].

Other Types

Other and less common forms of diabetes include gestational diabetes mellitus (GDM), which is a condition acquired during pregnancy; monogenic diabetes (including maturity-onset diabetes of the young, MODY); and secondary diabetes, caused by other ailments or by certain medications [8].

Weaknesses of Existing Interventions

However, these conventional approaches are predominantly symptomatic, focusing on glucose control rather than addressing the underlying pathogenic mechanisms. They are often limited by incomplete efficacy, the risk of hypoglycemia, treatment burdens, and an inability to halt the progressive decline in β-cell function or prevent long-term complications [9]. In T1DM, lifelong insulin replacement does not counteract the ongoing autoimmune destruction of β-cells. In T2DM, existing pharmacotherapy often fails to arrest the progressive β-cell failure and insulin resistance driving the disease [10]. These significant limitations highlight a clear unmet clinical need for interventions capable of modifying the disease course, restoring physiological regulation, and potentially inducing remission. The heterogeneity in pathogenesis is reflected in the disease classification. While T1DM and T2DM constitute the majority of cases, other forms such as gestational diabetes, monogenic diabetes (e.g., MODY), and secondary diabetes are increasingly recognized, each with distinct etiologies that may demand tailored therapeutic strategies.

Lifestyle Interventions (Diet, Exercise)

Together, there is strong evidence from clinical trials such as the Diabetes Prevention Program (DPP) that intensive lifestyle change prevents the occurrence of type 2 diabetes by 4560 percent in people at high risk [11]. These advantages are mediated by a group of physiologically related processes (Figure 2).

Figure 2: Mechanistic pathways linking lifestyle interventions to improved metabolic outcomes in diabetes

The important pathways involve enabling skeletal muscle and liver insulin sensitivity through AMPK activation and GLUT4 translocation, systemic inflammation reduction, and 2 -cell functionality through the reduction of glucolipotoxicity [12]. The schematic outlines the main biological processes of how diet adjustment (caloric restriction, high fiber, low glycemic load) and physical activity produce their positive influence. They are: (1) Enhanced Insulin Sensitivity: Stimulation of AMPK in muscle and liver, increasing glucose uptake and decreasing hepatic gluconeogenesis; (2) -Cell Preservation: Reduction of glucolipotoxicity, reducing metabolic stress on pancreatic -cells; (3) Palliative of Inflammation: Suppression of adipose tissue production of pro-inflammatory cytokines (e.g., TNF- a, IL-6); and (4 All these combined routes lead to a better glycemic regulation, weight loss, and cardiovascular risk.

DOI: https://doi.org/10.54393/pbmj.v9i1.1325

Stem Cell Therapy

In either type 1 diabetes (T1D) or type 2 diabetes (T2D), stem cell therapy is expected to replace or regenerate insulin-generating pancreatic 8-cells that have been destroyed in diabetes or are dysfunctional. The pluripotent stem cells (PSCs), such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), can be induced into glucose-responsive 6 -like cells, and this presents a potentially inexhaustible source of cell source to be used in transplantation [10]. According to the most recent clinical trials, like those of ViaCyte, the safety and initial effectiveness of encapsulated stem-cell-derived pancreatic progenitors in people with T1D have been noted. A decisive trade-off exists in the selection of the source of stem cells in terms of efficacy, safety, ethical issues, and stage of development.

Gene Therapy

The goal of gene therapy is to fix the genetic or functional defects of diabetes. The expression of the β-cell protective genes (e.g., PDX1, MafA) in T1D or the regulation of genes related to insulin sensitivity (e.g., GCKR, PPARG) in T2D might be used as strategies, and CRISPR/Cas9 can provide precise editing abilities [13]. Whereas preclinical models promise, there is a complex array of translational issues that prevent clinical implementation. The barriers to delivery are paramount; there is still difficulty in attaining efficient, targeted, and sustained delivery to the pancreatic or hepatic tissues. Viral vectors (e.g., AAV) are associated with immunogenicity, whereas non-viral approaches are characterized by low efficacy. It does not have long-term safety, and there is the risk of off-target edits, immune response to edited cells or delivery vectors, and oncogenesis as a result of potentially insertional mutagenesis [14]. Moreover, there is an extensive and dynamic regulatory route through which gene therapies have to pass, which is a potential obstacle. The clinical trial design is complex, long-lasting, and expensive due to the requirements by agencies such as the FDA and EMA to provide exhaustive preclinical information on whether the vectors are distributed, genotoxic, and long-term follow-up plans [15]. These bottlenecks on the delivery, safety, and regulatory side need to be overcome before gene therapy can be translated from a great idea to a clinical therapy that will help diabetics.

Immunotherapy

In other cases, type 1 diabetes requires immunotherapy. The etiology of T1DM is autoimmune destruction of β-cells; immunotherapy is an option for the future. The monoclonal antibodies are among the strategies and are applicable to monitor the immunological responses, vaccines against the diabetogenic antigens, and regulatory T-cell (Treg) therapy [16]. In the United States, recently, a monoclonal antibody, teplizumab, which targets T cell receptor CD3, has been approved to delay the onset of T1DM in those at high risk [17]. Other clinical trials are investigating other agents that either preserve the remaining β-cell or rebuild immune tolerance. The major challenges are the achievement of long-term remission and the minimization of adverse effects such as immunosuppression [18].

Nanotechnology in Diabetes

Nanotechnology offers transformative platforms for diabetes care, primarily through smart insulin delivery systems (e.g., glucose-responsive nanoparticles, hydrogels, microneedle patches) and advanced nanobiosensors for continuous glucose monitoring. These systems promise autonomous, physiologically responsive glycemic control, potentially reducing hypoglycemic risk and treatment burden [19]. However, translating these promising preclinical concepts into reliable, widely available therapies faces several formidable translational challenges.

Digital Health and Artificial Intelligence

Artificial intelligence (AI) has become an essential tool of diabetes care within a selected period of time [20]. Machine learning will be capable of calculating the probability of getting diabetes, the most effective dose of the insulin therapy, and the tailored treatment recommendations. The AI-based continuous glucose monitors (CGMs) and mobile health apps that allow monitoring glucose levels, diet, and exercise in real-time are now in existence. The so-called artificial pancreas (AI-controlled closed-loop insulin pumps) is an example, which is implemented to optimize insulin and better glycemic control based on the reduction in the incidence of hypoglycemia. Besides treatment, AI-based systems are also providing the prospect of the early detection of diabetic complications such as retinopathy due to retinal imaging [21].

Gut Microbiome and Probiotics

The gut microbiome has emerged as a major regulator role in host metabolism and glucose homeostasis [22]. Dysbiosis or changes in the composition of microbes have been linked to insulin resistance and T2DM. The experimental therapy is supposed to restore the microbial balance, which is based on probiotics, prebiotics, dietary fibers, and fecal microbial transplantation (FMT) [23]. Animal research and small clinical trials suggest that insulin sensitivity and glycemic control can be improved with the help of certain bacterial strains, such as Akkermansia muciniphila and Lactobacillus species. In spite of the promising nature of the field, it requires larger randomized controlled trials in order to establish efficacy

DOI: https://doi.org/10.54393/pbmj.v9i1.1325

and safety [12].

Transplant and Regeneration Medicine

Whereas the provision of the cellular raw material is done by the stem cell research field, the regenerative medicine and transplantation field is dedicated to the challenging engineering aspect of delivering and maintaining the cells in vivo. Allogeneic islet transplantation (the Edmonton protocol) is the historical standard that demonstrates that cell replacement can be used to restore insulin independence, but that has to be accompanied by life-long immunosuppression, and there is a shortage of donors [24]. Long-term graft survival without the use of immunosuppression is hence the primary aim of the central pursuit. This has triggered the promotions in immunoisolation techniques based on semi-permeable biomaterials. The existing encapsulation techniques strive to allow the two-way diffusion of oxygen, nutrients, insulin, and glucose and protect the graft against immune cells and antibodies [25]. The optimal response to fibrotic overgrowth (the foreign body response) is by optimizing biomaterial properties, which include the porosity, surface chemistry, and mechanical strength of the polyethersulfone or synthetic hydrogels, which starve encapsulated islets of oxygen [24]. There are new strategies of macroencapsulation (implantable, retrievable chambers) and microencapsulation (coating individual islands or clusters). One of the brightest examples is the current clinical translation of stem-cell-derived pancreatic endoderm cells in a framework of macroencapsulation devices that seek to offer a controlled environment of cell growth and functionality [26]. Combining angiogenic factors and oxygen-capable materials in these structures is one of the future directions in order to improve the graft vascularization and viability, which is the main limitation to long-term graft survival of a functional bioartificial pancreas.

Literature Search Strategy

This narrative review aimed to explore the innovative therapeutic paradigms of diabetes in detail. A systematic search of the literature in the databases of PubMed, Scopus, and Web of Science was carried out, and articles published from January 2019 to December 2024 were selected. The keywords were the following: diabetes mellitus, novel therapy, stem cell, regenerative medicine, immunotherapy, gene therapy, nanotechnology, artificial intelligence, digital health, and microbiome. The inclusion criteria gave priority to original research articles, clinical trials, systematic reviews, and meta-analyses, which were published in English. We filtered out studies not in English, and those where conventional therapies alone were studied without new mechanisms, and those that had been published before 2019, with exceptions being seminal works. Relevant information on mechanisms, efficacy, safety, and obstacles was identified and systematically synthesized thematically to give a critical picture of the current state of the field and the future.

Challenges and Limitations of Diabetes Management

High manufacturing costs and complex logistics for cell/gene therapies and advanced devices currently restrict them to affluent healthcare systems, exacerbating global health inequities [27] (Table 1).

Table 1: The challenges and limitations of novel therapeutic approaches for diabetes management

Specific Challenge	Explanation	References
Economic Constraint	Cell- and gene-based therapies are expensive to develop, manufacture, and deliver. Infrastructure, regulation, and quality control further increase costs, limiting accessibility.	[28]
Accessibility In Low-Income Countries	Many low- and middle-income countries lack specialized facilities, regulatory systems, and cold-chain logistics necessary for novel therapies. Access is often restricted to wealthy or urban populations.	[29]
Ethical Concerns – Gene Therapy	Gene editing raises moral concerns about heritable modifications, consent, and long-term effects. Risk of off-target mutations and misuse.	[30]
Ethical Concerns – Stem Cells	Use of embryonic stem cells raises ethical debates over embryo destruction, donor consent, and tumor formation risk.	[31]
Clinical Trial Limitations	High variability in stem cell types, dosages, and delivery routes makes it difficult to generalize findings across populations.	[32]
Insufficient Long-Term Data	Many trials show short-term benefits but lack evidence on durability, immune response, and tumorigenicity over extended periods.	[33]
Immunological Risks	In stem cell and transplant therapies, immune reactions and graft rejection remain significant barriers despite encapsulation technologies.	[34]
Regulatory Barriers	Different countries have varying regulations for gene editing, stem cell use, and nanomedicine, delaying translation to clinical practice.	[35]
Technological Challenges	Large-scale production and consistent differentiation of β-cells remain technically demanding.	[36]
Cost-Effectiveness	Novel interventions are not yet cost-effective compared to standard insulin therapy and oral drugs.	[37]

DOI: https://doi.org/10.54393/pbmj.v9i1.1325

Limited Evidence Base	More large-scale, long-term RCTs are required to confirm benefits, optimize protocols, and assess sustainability.	[38]

Thus, the study of scalable, automatable manufacturing (e.g., the scale-up of production with stem cells in bioreactors) and cheap biomaterials is not only a technical but also an ethical necessity. Second, the attainment of sustained efficacy and chronic safety is an essential validation gap of the majority of approaches. In the case of regenerative and immunotherapies, it is necessary to show long-term glycemic control and immune tolerance compared to temporary studies. At the same time, to obtain regulatory approval and popular acceptance, the creation of effective, standardized safety surveillance systems of such risks as tumorigenicity (stem cells), off-target effects (gene editing), and algorithmic bias (AI) is an initial step [39]. Lastly, hybrid regulatory approaches of combination products (e.g., cell device) and AI-as-a-medical-device should be developed. Research, industry, and regulators must work together to specify endpoints and evidence standards of such new therapeutic classes, or promising innovations may remain stagnant in development, developmental dead ends [40]. These three issues that are prioritized, namely, affordability, lasting safety/efficacy, and regulatory clarity, will play a crucial role in determining which new paradigms can shift into the realm of clinical reality on a broad scale.

DISCUSSION

Immunotherapy aims to disrupt the autoimmune pathogenesis of type 1 diabetes (T1D), representing a paradigm shift from managing hyperglycemia to modifying the underlying disease. The recent FDA approval of teplizumab, an anti-CD3 monoclonal antibody, to delay the onset of clinical T1D in high-risk individuals marks a significant milestone, validating the concept of immune intervention [15]. However, its modest efficacy and transient effects underscore that monotherapy is unlikely to induce lasting remission, highlighting the critical need for combination strategies and precision patient selection. The therapeutic landscape extends beyond a single agent. Current investigational approaches include: 1) Antigen-specific therapies (e.g., GAD65, proinsulin peptides) to induce immune tolerance; 2) Cytokine-targeting agents (e.g., anti-IL-21, anti-IL-6) to modulate the inflammatory milieu; and 3) Cellular therapies, notably the expansion and infusion of regulatory T cells (Tregs) to restore immune balance [40]. Combining these modalities—for instance, an anti-CD3 agent to reset the immune system followed by an antigen-specific vaccine to establish lasting tolerance—is a key focus of next-generation clinical trials. Success in this field is heavily dependent on identifying the optimal therapeutic window and stratifying patients using predictive biomarkers. Intervention is most effective during the pre-symptomatic stage or at clinical onset when a substantial reservoir of functional β-cells remains. Biomarkers such as autoantibody titers, T-cell phenotype assays, and genetic risk scores are being refined to identify individuals most likely to respond to specific immunotherapies and to monitor treatment efficacy [41]. The overarching challenge remains achieving durable immune tolerance without causing generalized immunosuppression, a goal that requires continued innovation in both therapeutic agents and the biomarkers used to guide their deployment. However, its widespread application is restricted because of its high price, inaccessibility in low-income regions, and unpredictability regarding the regulation. Moreover, the ethics in gene editing and embryonic stem cell has its opportunities as well as challenges that transcend science and extend to society [42]. The current trends in the curative approaches to diabetes give rise to the potential and the challenge of the conventional glucose-lowering systems [43]. However, this has not yielded consistent results due to the heterogeneity of the type of stem cells, dosage, route of administration, and patient selection, and the long-term durability and standardization of the process remain a doubtful issue. All of these combined prove the fact that safety is accepted, but the problems of immune response and tumorigenicity remain a concern that has yet to be resolved. Generally, the literature suggests a paradigm shift towards disease modification of glucose as opposed to symptomatic regulation of glucose [44]. To date, the most promising evidence is stem cell and immunotherapy therapies, but they should be validated in large, long-term randomized trials. Future research should center on early intervention, combination treatment methods, and alternative medicine, and the problem of cost, availability, and ethical matters. When such new strategies overcome these hurdles, it is then and only then that they can be translated into clinical practice and potentially revolutionize care provision in diabetes especially in patients whose β-cells have been severely destroyed as the case is, in patients with long-lived type 2 diabetes and in diabetes in preclinical phase or early-stage type 1 diabetes where some of the β-cells continue to survive. The most likely scenario is that the management of the future will require the two synergies: the immune modulation of the existing β-cells, and the regenerative solutions relying on the replacement of the already lost ones.

The primary limitations of these emerging therapies include high manufacturing costs, limited accessibility in low- and middle-income countries, insufficient long-term safety and efficacy data, and ethical concerns surrounding gene editing and stem cell use. Additionally, variability in

DOI: https://doi.org/10.54393/pbmj.v9i1.1325

treatment protocols and patient response hinders broad clinical application. Future efforts should prioritize scalable, cost-effective manufacturing processes, conduct large-scale long-term clinical trials, and develop clear regulatory pathways. Research should also focus on personalized combination therapies, early intervention strategies, and equitable global access to ensure these innovations benefit diverse patient populations.

CONCLUSION

Diabetes mellitus remains a major global health challenge, with conventional therapies limited to symptom control rather than cure. Emerging treatments such as stem cell therapy, immunotherapy, nanotechnology, and AI-driven personalized medicine offer a paradigm shift by targeting the root causes of the disease. Overcoming challenges related to cost, regulation, and long-term validation will be essential to translate these innovations into clinical practice.

Authors' Contribution

Conceptualization: AS
Methodology: AS
Formal analysis: AS
Writing and drafting: AS
Review and editing: AS

All authors approved the final manuscript and take responsibility for the integrity of the work.

Conflicts of Interest

The authors declare no conflict of interest.

Source of Funding

The author received no financial support for the research, authorship and/or publication of this article.

REFERENCES

[1] Sarkar BK, Akter R, Das J, Das A, Modak P, Halder S *et al.* Diabetes Mellitus: A Comprehensive Review. Journal of Pharmacognosy and Phytochemistry. 2019; 8(6): 2362-2371.

[2] Razaq RA, Mahdi JA, Jawad RA. Information About Diabetes Mellitus. Journal of the University of Babylon for Pure and Applied Sciences. 2020 Dec; 28(3): 243-52.

[3] Nathan DM. Diabetes: Advances In Diagnosis and Treatment. Jama. 2015 Sep; 314(10): 1052-1062. doi: 10.1001/jama.2015.9536.

[4] Kumar R, Saha P, Kumar Y, Sahana S, Dubey A, Prakash O. A Review on Diabetes Mellitus: Type1 and Type2. World Journal of Pharmacy and Pharmaceutical Sciences. 2020 Aug; 9(10): 838-850.

[5] Kostopoulou E, Sinopidis X, Fouzas S, Gkentzi D, Dassios T, Roupakias S *et al.* Diabetic Ketoacidosis in Children and Adolescents; Diagnostic and Therapeutic Pitfalls. Diagnostics. 2023 Aug; 13(15): 1-14. doi: 10.3390/diagnostics13152602.

[6] Blagosklonny MV. TOR-Centric View on Insulin Resistance and Diabetic Complications: Perspective for Endocrinologists and Gerontologists. Cell Death and Disease. 2013 Dec; 4(12): 1-8. doi: 10.1038/cddis.2013.506.

[7] Thaker VV. Genetic and Epigenetic Causes of Obesity. Adolescent Medicine: State of the Art Reviews. 2017 Nov; 28(2): 379-405. doi: 10.1542/9781581109405-genetic.

[8] Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT *et al.* Diabetes Mellitus: Classification, Mediators, and Complications; A Gate to Identify Potential Targets for The Development of New Effective Treatments. Biomedicine and Pharmacotherapy. 2023 Dec; 168: 1-25. doi: 10.1016/j.biopha.2023.115734.

[9] Tegegne BA, Adugna A, Yenet A, Yihunie Belay W, Yibeltal Y, Dagne A *et al.* A Critical Review on Diabetes Mellitus Type 1 And Type 2 Management Approaches: From Lifestyle Modification to Current and Novel Targets and Therapeutic Agents. Frontiers In Endocrinology. 2024 Oct; 15: 1-20. doi: 10.3389/fendo.2024.1440456.

[10] Susilawati E, Levita J, Susilawati Y, Sumiwi SA. Review of The Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients. Medical Sciences. 2023 Aug; 11(3): 1-12. doi: 10.3390/medsci11030050.

[11] Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, Del Prato S *et al.* Insulin therapy in people with type 2 diabetes: opportunities and challenges. Diabetes care. 2014 Jun; 37(6): 1499-508. doi: 10.2337/dc13-2743.

[12] Jasim ME and Abdul-Razzaq NE. A Comparative Study Between Metformin and Insulin on Biochemical Variables in Diabetic Patients. Endocrine and Metabolic Science. 2024 Sep; 16: 1-6. doi: 10.1016/j.endmts.2024.100206.

[13] Ke QI, Kroger CJ, Clark M, Tisch RM. Evolving Antibody Therapies for the Treatment of Type 1 Diabetes. Frontiers in Immunology. 2021 Feb; 11: 1-16. doi: 10.3389/fimmu.2020.624568.

[14] Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB *et al.* Cross-Talk Between Akkermansia Muciniphila and Intestinal Epithelium Controls Diet-Induced Obesity. Proceedings of the National Academy of Sciences. 2013 May; 110(22): 9066-9071. doi: 10.1073/pnas.1219451110.

DOI: https://doi.org/10.54393/pbmj.v9i1.1325

[15] Gómez-Hernández A, de Las Heras N, López-Pastor AR, García-Gómez G, Infante-Menéndez J, González-López P *et al.* Severe Hepatic Insulin Resistance Induces Vascular Dysfunction: Improvement by Liver-Specific Insulin Receptor Isoform A Gene Therapy in A Murine Diabetic Model. Cells. 2021 Aug; 10(8): 1-14. doi: 10.3390/cells10082035.

[16] Eggenhuizen PJ, Ng BH, Ooi JD. Treg Enhancing Therapies to Treat Autoimmune Diseases. International Journal of Molecular Sciences. 2020 Sep; 21(19): 1-18. doi: 10.3390/ijms21197015.

[17] Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ *et al.* An Anti-CD3 Antibody, Teplizumab, In Relatives at Risk for Type 1 Diabetes. New England Journal of Medicine. 2019 Aug; 381(7): 603-13. doi: 10.1056/NEJMoa1902226.

[18] López MM, Valenzuela JE, Álvarez FC, López-Álvarez MR, Cecilia GS, Paricio PP. Long-Term Problems Related to Immunosuppression. Transplant Immunology. 2006 Dec; 17(1): 31-5. doi: 10.1016/j.trim.2006.09.018.

[19] Shapiro AJ, Thompson D, Donner TW, Bellin MD, Hsueh W, Pettus J *et al.* Insulin Expression and C-Peptide in Type 1 Diabetes Subjects Implanted with Stem Cell-Derived Pancreatic Endoderm Cells in an Encapsulation Device. Cell Reports Medicine. 2021 Dec; 2(12): 1-17. doi: 10.1016/j.xcrm.2021.100466.

[20] Dankwa-Mullan I, Rivo M, Sepulveda M, Park Y, Snowdon J, Rhee K. Transforming Diabetes Care Through Artificial Intelligence: The Future is Here. Population Health Management. 2019 Jun; 22(3): 229-242. doi: 10.1089/pop.2018.0129.

[21] Gupta S. AI-Powered Approaches for Diabetes Detection in Healthcare and Monitoring: A Review of Recent Advances. Journal of Global Trends in Artificial Intelligence. 2025 Jul; 1(1): 7-14.

[22] Lee JY, Tsolis RM, Bäumler AJ. The Microbiome and Gut Homeostasis. Science. 2022 Jul; 377(6601). doi: 10.1126/science.abp9960.

[23] Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F *et al.* A Metagenome-Wide Association Study of Gut Microbiota in Type 2 Diabetes. Nature. 2012 Oct; 490(7418): 55-60. doi: 10.1038/nature11450.

[24] Pires IG, e Souza JA, de Melo Bisneto AV, Passos XS, Carneiro CC. Clinical Efficacy of Stem-Cell Therapy on Diabetes Mellitus: A Systematic Review and Meta-Analysis. Transplant Immunology. 2022 Dec; 75. doi: 10.1016/j.trim.2022.101740.

[25] Ogieuhi IJ, Agbo CE, Ajekiigbe VO, Anthony CS, Onyehalu JC, Nwankwo CK *et al.* Stem Cell-Derived Pancreatic Beta Cells: A Step Closer to Functional Diabetes Treatment. BioMed Central Endocrine Disorders. 2025 Jul; 25(1): 1-20. doi: 10.1186/s12902-025-01997-y.

[26] Kashbour M, Abdelmalik A, Yassin MN, Abed M, Aldieb E, Abdullah DM *et al.* Mesenchymal Stem Cell-Based Therapy for Type 1 and 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetology and Metabolic Syndrome. 2025 Jun; 17(1): 1-20. doi: 10.1186/s13098-025-01619-6.

[27] Kaushal A, Musafir A, Sharma G, Rani S, Singh RK, Kumar A *et al.* Revolutionizing Diabetes Management Through Nanotechnology-Driven Smart Systems. Pharmaceutics. 2025 Jun; 17(6): 1-27. doi: 10.3390/pharmaceutics17060777.

[28] Elverum K and Whitman M. Delivering Cellular and Gene Therapies to Patients: Solutions for Realizing the Potential of The Next Generation of Medicine. Gene Therapy. 2020 Dec; 27(12): 537-44. doi: 10.1038/s41434-019-0074-7.

[29] Bors C, Christie A, Gervais D, Wright Clayton E. Improving Access to Medicines in Low-Income Countries: A Review of Mechanisms. The Journal of World Intellectual Property. 2015 Mar; 18(2): 1-28. doi: 10.1111/jwip.12032.

[30] Gyngell C, Douglas T, Savulescu J. The Ethics of Germline Gene Editing. Journal of Applied Philosophy. 2017 Aug; 34(4): 498-513. doi: 10.1111/japp.12249.

[31] Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N *et al.* Ethical and Safety Issues of Stem Cell-Based Therapy. International Journal of Medical Sciences. 2018 Jan; 15(1): 1-10. doi: 10.7150/ijms.21666.

[32] Kanelidis AJ, Premer C, Lopez J, Balkan W, Hare JM. Route of Delivery Modulates the Efficacy of Mesenchymal Stem Cell Therapy for Myocardial Infarction: A Meta-Analysis of Preclinical Studies and Clinical Trials. Circulation Research. 2017 Mar; 120(7): 1139-1150. doi: 10.1161/CIRCRESAHA.116.309819.

[33] Skyler JS and Ricordi C. Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man. Diabetes. 2011 Jan; 60(1): 1-8.

[34] Desai T and Shea LD. Advances in Islet Encapsulation Technologies. Nature Reviews Drug Discovery. 2017 May; 16(5): 338-350.

[35] Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD. Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities. Medical Decision Making. 2010 May; 30(3): 328-340.

[36] Pellegrini S, Zamarian V, Sordi V. Strategies to Improve the Safety of Ipsc-Derived B Cells for B Cell

DOI: https://doi.org/10.54393/pbmj.v9i1.1325

Replacement in Diabetes. Transplant International. 2022 Aug; 35: 1-15.
[37] Bosetti R. Cost–Effectiveness of Nanomedicine: The Path to a Future Successful and Dominant Market. Nanomedicine. 2015 Jul; 10(12): 1851-1853.
[38] Trounson A and McDonald C. Stem Cell Therapies in Clinical Trials: Progress and Challenges. Cell Stem Cell. 2015 Jul; 17(1): 11-22.
[39] Zhang K, Qi Y, Wang W, Tian X, Wang J, Xu L *et al.* Future Horizons in Diabetes: Integrating AI and Personalized Care. Frontiers in Endocrinology. 2025 Mar; 16: 1-9.
[40] Ansah EO. Ethical Challenges and Controversies in The Practice and Advancement of Gene Therapy. Advances in Cell and Gene Therapy. 2022 Aug; 1(1): 1-5.
[41] Afshar L, Aghayan HR, Sadighi J, Arjmand B, Hashemi SM, Basiri M *et al.* Ethics of Research on Stem Cells and Regenerative Medicine: Ethical Guidelines in The Islamic Republic of Iran. Stem Cell Research and Therapy. 2020 Sep; 11(1): 1-5.
[42] Sintov E, Rosado-Olivieri EA, Leite N, Straubhaar J, Veres A, Boulanger K *et al.* 402.4: Genetic Approaches to Attain Hypo-immunogenic Human Stem Cell-Derived Islets for Transplantation. Transplantation. 2021 Dec; 105(12): 1.
[43] Hyun I. The Bioethics of Stem Cell Research and Therapy. The Journal of Clinical Investigation. 2010 Jan; 120(1): 71-75.
[44] Ranjbaran H, Mohammadi Jobani B, Amirfakhrian E, Alizadeh-Navaei R. Efficacy of Mesenchymal Stem Cell Therapy on Glucose Levels in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of Diabetes Investigation. 2021 May; 12(5): 803-810.